Figure 9: Enhanced uptake and toxicity of doxorubicin by GRR10W4 in melanoma cells.
From: Pronounced peptide selectivity for melanoma through tryptophan end-tagging
(a) Representative confocal microscopy images of peptide and doxorubicin uptake in RPMI 7951 melanoma cells and (b) quantification of doxorubicin uptake after co-treatment with doxorubicin and peptides in RPMI 7951 and MeWo cells. For both (a,b), RPMI 7951 cells or MeWo cells were treated with 0.1 μM doxorubicin and 5 μM GRR10-Alexa488 or 5 μM GRR10W4-Alexa488 for 2 h and subjected to confocal microscopy. (c) Toxicity of co-treatment with doxorubicin and GRR10 or GRR10W4 peptides on RPMI 7951 and MeWo cells. Cells were treated with 0.1 μM doxorubicin and 5 μM GRR10 or 5 μM GRR10W4 for 24 h and subjected to cell viability assay by MTT. *p < 0.05 compared to no treatment group.
